Kroger executive named CEO of The Little Clinic
CINCINNATI Kroger has appointed Kroger executive Michael Stoll to serve as CEO of The Little Clinic business.
Stoll brings 34 years of experience with Kroger in corporate benefits, human resources management and store operations to his new role. In his most recent position as VP corporate benefits, Stoll played a key role in developing the healthcare strategy and pension plans for Kroger’s 334,000 full- and part-time associates.
Promoted to VP corporate benefits, succeeding Stoll, is Theresa Monti. Prior to her promotion, Monti served as director of corporate health and welfare benefit programs for Kroger. In her new role, she will lead the development, implementation and administration of policies and strategies for the company-sponsored health, welfare and retirement benefit plans. Prior to joining Kroger in 1999, she held national account management positions with both Kaiser Permanente and Prudential Health Care.
“The Little Clinic is an essential part of Kroger’s commitment to health and wellness for all of the customers we serve. Mike’s extensive experience in healthcare benefits and customer insight will guide us as we continue to look for innovative ways to build on the shared expertise in our clinics and our stores,” stated David Dillon, chairman and CEO of Kroger.
The Little Clinic, which Kroger acquired in February, operates clinics inside select Kroger stores, including Fry’s in Arizona, King Soopers in Colorado, and Kroger stores in Kentucky, Ohio and Tennessee. The relationship between Kroger and The Little Clinic began in 2003 when Kroger opened its first Little Clinic in a Kroger store in Louisville, Ky.
Perrigo to manufacture Analpram HC for Ferndale Labs
ALLEGAN, Mich, Ferndale Labs has named generic drug maker Perrigo as the manufacturer of an authorized generic version of a topical skin cream, Perrigo announced Thursday.
The drug, Analpram HC, is a topical anesthetic and corticosteroid for relieving inflammatory and pruritic forms of corticosteroid-responsive dermatosis. Under the deal, Perrigo will also have the opportunity to distribute authorized generics of other Ferndale drugs.
“We are excited that Ferndale has chosen Perrigo as their preferred partner for authorized generics,” Perrigo chairman and CEO Joseph Papa said.
Par wins Zegerid patent suit
WOODCLIFF LAKE, N.J. The U.S. District Court for the District of Delaware has ruled in favor of generic drug maker Par Pharmaceutical in a patent litigation suit over a drug used to treat acid reflux, Par announced Thursday.
The court ruled that the University of Missouri’s patents covering omeprazole and sodium bicarbonate capsules in the 20-mg/1.1-g and 40-mg/1.1-g strengths and oral suspension powders in the 20-mg/1.68-g and 4- mg/1.68-g strengths are invalid. The Food and Drug Administration recently was granted tentative approval for both strengths of the capsule version.
Omeprazole and sodium bicarbonate is a generic version of Santarus’s drug Zegerid. Patents for the capsules and oral suspension powder are set to expire in 2016, according to FDA records. According to Santarus financial data, Zegerid capsules and oral suspension powder had combined sales of $119.3 million in 2009.
Santarus said Wednesday that it would appeal the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit.